Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

EMBO Reports

Volumn 12, Issue 12, 2011, Pages 1300-1305

  Surdo, Paola Lo ^a,d   Bottomley, Matthew J ^a,d   Calzetta, Alessandra ^a   Settembre, Ethan C ^b,e   Cirillo, Agostino ^a,f   Pandit, Shilpa ^c   Ni, Yan G ^c   Hubbard, Brian ^c   Sitlani, Ayesha ^c   Carfí, Andrea ^a,e  

^a IRBM   (Italy)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^e NOVARTIS PHARMA AG   (Switzerland)

^f NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

hypercholesterolaemia; LDL; PCSK9; receptor; structure

Indexed keywords

EPIDERMAL GROWTH FACTOR; KEXIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SOLVENT; SUBTILISIN; UNCLASSIFIED DRUG;

ACIDITY; ALKALINITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; PH; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SOLVENT EFFECT; STRUCTURE ANALYSIS;

DOWN-REGULATION; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, MOLECULAR; PROPROTEIN CONVERTASES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEOLYSIS; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; SURFACE PLASMON RESONANCE;

EID: 82555187008     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/embor.2011.205     Document Type: Article

References (35)

1. Abifadel M, Rabes JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, Boileau C (2009) Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 30: 520-529
2. 2+ affinity of the fifth binding module of the LDL receptor. J Biol Chem 283: 22670-22679
3. Beglova N, Jeon H, Fisher C, Blacklow SC (2004) Cooperation between fixed and low pH-inducible interfaces controls lipoprotein release by the LDL receptor. Mol Cell 16: 281-292 (Pubitemid 39388842)
4. Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG (2006) The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 281: 30561-30572 (Pubitemid 44582112)
5. Bottomley MJ et al (2009) Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem 284: 1313-1323
6. Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47 (Pubitemid 16037973)
7. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354: 1264-1272
8. Cunningham D et al (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 14: 413-419 (Pubitemid 46685885)
9. Davis CG, Goldstein JL, Sudhof TC, Anderson RG, Russell DW, Brown MS (1987) Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. Nature 326: 760-765 (Pubitemid 17057795)
10. Essalmani R, Susan-Resiga D, Chamberland A, Abifadel M, Creemers JW, Boileau C, Seidah NG, Prat A (2011) In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem 286: 4257-4263
11. Esser V, Limbird LE, Brown MS, Goldstein JL, Russell DW (1988) Mutational analysis of the ligand binding domain of the low density lipoprotein receptor. J Biol Chem 263: 13282-13290
12. Fisher TS et al (2007) PCSK9-dependent LDL receptor regulation: effects of pH and LDL. J Biol Chem 282: 20502-20512 (Pubitemid 47100016)
13. Goldstein JL, Basu SK, Brunschede GY, Brown MS (1976) Release of low density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans. Cell 7: 85-95
14. Hampton EN, Knuth MW, Li J, Harris JL, Lesley SA, Spraggon G (2007) The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci USA 104: 14604-14609 (Pubitemid 350003191)
15. Horton JD, Cohen JC, Hobbs HH (2009) PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 50 (Suppl): S172-S177
16. Huang S, Henry L, Ho YK, Pownall HJ, Rudenko G (2010) Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor. J Lipid Res 51: 297-308
17. Jeon H, Shipley GG (2000) Vesicle-reconstituted low density lipoprotein receptor. Visualization by cryoelectron microscopy. J Biol Chem 275: 30458-30464
18. Jeon H, Meng W, Takagi J, Eck MJ, Springer TA, Blacklow SC (2001) Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair. Nat Struct Biol 8: 499-504 (Pubitemid 32525007)
19. Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J (2008) Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA 105: 1820-1825 (Pubitemid 351439423)
20. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD (2006) Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 116: 2995-3005 (Pubitemid 44684484)
21. Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE (2008) Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet 72: 485-498 (Pubitemid 351850090)
22. Mayer G, Poirier S, Seidah NG (2008) Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem 283: 31791-31801
23. Mousavi SA, Berge KE, Berg T, Leren TP (2011) Affinity and kinetics of PCSK9 binding to LDL receptors on HepG2 cells. FEBS J 278: 2938-2950
24. Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, McPherson PS, Attie AD, Prat A, Seidah NG (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8: 718-732 (Pubitemid 46785153)
25. NCEP-Panel (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421
26. Ni YG et al (2010) A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores LDL-uptake. J Biol Chem 285: 12882-12891
27. Palmer-Smith H, Basak A (2010) Regulatory effects of peptides from the pro and catalytic domains of proprotein convertase subtilisin/kexin 9 (PCSK9) on low-density lipoprotein receptor (LDL-R). Curr Med Chem 17: 2168-2182
28. Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, Shan B, Walker NP (2007) The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 15: 545-552 (Pubitemid 46702689)
29. Ren G, Rudenko G, Ludtke SJ, Deisenhofer J, Chiu W, Pownall HJ (2010) Model of human low-density lipoprotein and bound receptor based on cryoEM. Proc Natl Acad Sci USA 107: 1059-1064
30. Rudenko G, Henry L, Henderson K, Ichtchenko K, Brown MS, Goldstein JL, Deisenhofer J (2002) Structure of the LDL receptor extracellular domain at endosomal pH. Science 298: 2353-2358 (Pubitemid 36014201)
31. Russell DW, Brown MS, Goldstein JL (1989) Different combinations of cysteine-rich repeats mediate binding of low density lipoprotein receptor to two different proteins. J Biol Chem 264: 21682-21688 (Pubitemid 20028736)
32. Yamamoto T, Lu C, Ryan RO (2011) A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor. J Biol Chem 286: 5464-5470
33. Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH (2008) Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci USA 105: 13045-13050
34. Zhao Z, Michaely P (2008) The epidermal growth factor homology domain of the LDL receptor drives lipoprotein release through an allosteric mechanism involving H190, H562, and H586. J Biol Chem 283: 26528-26537
35. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC, Hobbs HH (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 79: 514-523 (Pubitemid 44384260)